Source - LSE Regulatory
RNS Number : 9082W
ConvaTec Group PLC
28 April 2021
 

ConvaTec Group Plc

 

Scrip Dividend - Total Issued Shares

 

 

Reading, United Kingdom (28 April 2021)

The Board of Directors of ConvaTec Group Plc ("ConvaTec" or "the Company") proposed a final dividend in respect of 2020 of 3.983 cents per share ("Final Dividend"), subject to shareholder approval at the Annual General Meeting on 7 May 2021 ("AGM"). The Final Dividend is to be paid on 13 May 2021 to shareholders on the share register as at 6 April 2021 ("Record Date"). The dividend is payable in cash in sterling to holders of ordinary shares. On 5 March 2021, the Company announced that a scrip dividend would be made available for the Final Dividend, allowing shareholders to elect to receive their dividend in the form of new ordinary shares. The calculation price for the scrip dividend was announced on 12 April 2021.

Subject to the approval of the Final Dividend at the AGM, 9,475,532 ordinary shares of 10 pence each will be allotted and issued on 13 May 2021 by the Company to those shareholders who elected to receive the scrip dividend alternative. Elections for the scrip dividend were made in respect of 656,132,544 ordinary shares of 10 pence each, representing 32.74% of the Company's issued share capital. The shares will rank pari passu with the existing issued ordinary shares of the Company. Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List and to the London Stock Exchange for the shares to be admitted to trading.

Following the issue of shares under the scrip dividend scheme in respect of the Final Dividend, the Company's issued share capital will be 2,013,822,670 ordinary shares of 10 pence each.

Dealings in the shares issued under the scrip dividend scheme is expected to commence on 13 May 2021.

 

Details of the scrip dividend scheme are available at www.convatecgroup.com/investors.

TIMETABLE

Key dates in respect of the scrip dividend scheme for the Final Dividend are:

Ex-dividend Date

   1 April 2021

 

Record Date

6 April 2021

 

Scrip calculation price determined

1-9 April 2021 (inclusive)        

 

Scrip calculation price available and announced

                  12 April 2021

 

Mandate delivery deadline for Shares held in uncertificated form

3.00 p.m. on 22 April 2021

 

Mandate delivery deadline for Shares held in certificated form

5.00 p.m. on 22 April 2021

 

  Announcement of the total amount of new shares to be issued

                         28 April 2021

 

  Dividend payment date

                         13 May 2021

 

  Dispatch of statement in accordance with section 7 of Scheme

                         13 May 2021

 

Rules and share certificates, CREST accounts credited/updated,

and first day of dealings in New Shares

                                                                                                           

Enquiries

Analysts and Investors

Kate Postans, VP, Investor Relations

& Corporate Communications, ConvaTec                                 +44 (0)7826 447807

ir@convatec.com

 

Media

Buchanan: Charles Ryland / Chris Lane                                    +44 (0)207 466 5000                                                                                                        

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

 

 

 

 

# # #

END

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFFLSDITFIL
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.